Srikanth, P.
,
Chun, R. F.
Hewison, M.
Adams, J. S.
Bouillon, R.
Vanderschueren, D.
Lane, N.
Cawthon, P. M.
Dam, T.
Barrett-Connor, E.
Daniels, L. B.
Shikany, J. M.
Stefanick, M. L.
Cauley, J. A.
Orwoll, E. S.
Nielson, C. M.
Funding for this research was provided by:
National Institute on Aging (U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AR066160, R01 AR063910, P60 AR054731, K01 AR062655)
National Center for Advancing Translational Sciences (UL1 TR000128)
Merck (SRA-12-009)
Article History
Received: 22 September 2015
Accepted: 10 February 2016
First Online: 23 February 2016
Compliance with ethical standards
:
: Roger Bouillon received lecture fees from Amgen, Novartis, Novo Nordisk, Chugai, and Teijin and gave a license to a university patent on vitamin D analogs to Hybrigenix (France). Eric S. Orwoll consults for and has received research support from Merck, Lilly, and Amgen. Carrie Nielson, Priya Srikanth, Rene F Chun, Martin Hewison, John S Adams, Dirk Vanderschueren, Nancy E Lane, Peggy Cawthon, Tien Dam, Elizabeth Barrett-Connor, Lori B Daniels, James Shikany, Marcia L Stefanick, and Jane Cauley declare that they have no conflict of interest.